Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial.

Autor:	Sharma, Abhinav, Marques, Pedro, Neuen, Brendon L., Fletcher, Robert A., Slee, April, Rapattoni, Wally, Ang, Fernando G., Arnott, Clare, Levin, Adeera, Verma, Subodh, Perkovic, Vlado, Mahaffey, Kenneth W.
Předmět:	TYPE 2 diabetes HEART failure CANAGLIFLOZIN PROPORTIONAL hazards models PROGRESSION-free survival OLANZAPINE
Zdroj:	Diabetes, Obesity & Metabolism; Feb2024, Vol. 26 Issue 2, p758-762, 5p
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text